4D Molecular Therapeutics FDMT Software and Technology Licenses, Net
Software and Technology Licenses, Net at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about 4D Molecular Therapeutics's software and technology licenses, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 4D Molecular Therapeutics's software and technology licenses, net?
- 4D Molecular Therapeutics (FDMT) reported software and technology licenses, net of $9.86M in Q1 2026.
- How has 4D Molecular Therapeutics's software and technology licenses, net changed year-over-year?
- 4D Molecular Therapeutics's software and technology licenses, net increased by 40.0% year-over-year, from $7.04M to $9.86M.
- What is the long-term trend for 4D Molecular Therapeutics's software and technology licenses, net?
- Over 5 years (2020 to 2025), 4D Molecular Therapeutics's software and technology licenses, net has grown at a 72.5% compound annual growth rate (CAGR), from $602K to $9.19M.